Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Jefferies Foresees 100% US Tariff on Branded Drugs to Have Limited Impact on CN Drug Makers
Recommend 3 Positive 5 Negative 3 |
||||
|
||||
|
Two months after floating a 200% drug tariff threat, US President Donald Trump announced a 100% tariff on branded or patented drugs to promote domestic manufacturing, according to a Jefferies research report. Since Chinese drug makers have only minimal direct drug sales to the US market, and Chinese biotech firms can avoid tariff impacts through partnerships with multinational pharma companies, Jefferies estimated the impact would be restrained. As for CDMO companies, Jefferies predicted the increased production costs in the US to be borne by multinational pharma clients. WUXI BIO (02269.HK) has already established its capacity in the US with 4,000 liters in New Jersey and plans to add 36,000 liters by 2027. In contrast, Samsung Biologics has yet to set up a plant in the US. Investors are advised to consider buying WUXI BIO shares during price adjustments. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
